LILLY
🔴
Mission Statement
MISSION STATEMENT
Introduction
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is a premier global healthcare leader and
pharmaceutical pioneer. Founded in 1876 by Colonel Eli Lilly—a chemist and American Civil War veteran
dedicated to manufacturing high-quality pharmaceuticals in an era of unreliable medicines—the corporation
has shaped modern clinical care for 150 years. Lilly was the first company to mass-produce the polio vaccine
and commercialize human insulin using recombinant DNA technology. Today, Eli Lilly operates at the pinnacle
of the global biotechnology sector, deploying a workforce of over 50,000 specialists across operations
spanning more than 160 countries. The enterprise balances extensive legacy dominance in diabetes care
with rapid diversification into breakthrough clinical spaces, including obesity, oncology, immunology, and
neurodegenerative diseases.
Mission Statement
Eli Lilly aligns its global corporate purpose around continuous medical advancement and immediate patient
benefit:
"We make medicines that help people live longer, healthier, more active lives."
Strategic analysts evaluate the execution of this mission across three high-impact commercial pillars:
Discovery and Aggressive Innovation:
Investing heavily in R&D infrastructure to build deep scientific
complexity that acts as a strong competitive moat. This covers complex biological platforms including
incretins, amylins, siRNA, antibody-drug conjugates, and radiopharmaceuticals.
Therapeutic Outcome Optimization:
Structuring drug development around clear, measurable clinical
outcomes that enable value-based pricing and strong regulatory partnerships globally.
The Lilly 30x30 Initiative:
Driving strategic market expansion and public health enhancement by striving
to improve healthcare access for 30 million people living in resource-limited, vulnerable communities
annually by 2030.
1.
2.
3.
Eli Lilly and Company Strategic Blueprint
Page 1 of 3
